<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id><journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id><journal-id journal-id-type="publisher-id">bioinformatics</journal-id><journal-title-group><journal-title>Bioinformatics</journal-title></journal-title-group><issn pub-type="ppub">1367-4803</issn><issn pub-type="epub">1367-4811</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6853644</article-id><article-id pub-id-type="doi">10.1093/bioinformatics/btz465</article-id><article-id pub-id-type="publisher-id">btz465</article-id><article-categories><subj-group subj-group-type="heading"><subject>Applications Notes</subject><subj-group subj-group-type="category-toc-heading"><subject>Systems Biology</subject></subj-group></subj-group></article-categories><title-group><article-title>vulcanSpot: a tool to prioritize therapeutic vulnerabilities in cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Perales-Pat&#x000f3;n</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="btz465-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Di Domenico</surname><given-names>Tom&#x000e1;s</given-names></name><xref ref-type="aff" rid="btz465-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fustero-Torre</surname><given-names>Coral</given-names></name><xref ref-type="aff" rid="btz465-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pi&#x000f1;eiro-Y&#x000e1;&#x000f1;ez</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="btz465-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carretero-Puche</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="btz465-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tejero</surname><given-names>H&#x000e9;ctor</given-names></name><xref ref-type="aff" rid="btz465-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Valencia</surname><given-names>Alfonso</given-names></name><xref ref-type="aff" rid="btz465-aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>G&#x000f3;mez-L&#x000f3;pez</surname><given-names>Gonzalo</given-names></name><xref ref-type="aff" rid="btz465-aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2373-769X</contrib-id><name><surname>Al-Shahrour</surname><given-names>F&#x000e1;tima</given-names></name><xref ref-type="aff" rid="btz465-aff1">1</xref><xref ref-type="corresp" rid="btz465-cor1"/><!--<email>falshahrour@cnio.es</email>--></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Schwartz</surname><given-names>Russell</given-names></name><role>Associate Editor</role></contrib></contrib-group><aff id="btz465-aff1"><label>1</label>
<institution>Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO)</institution>, Madrid 28029, Spain</aff><aff id="btz465-aff2"><label>2</label>
<institution>Computational Biology Life Sciences Group, Barcelona Supercomputing Centre</institution>, Barcelona, Spain</aff><author-notes><corresp id="btz465-cor1">To whom correspondence should be addressed. E-mail: <email>falshahrour@cnio.es</email></corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="epub" iso-8601-date="2019-06-07"><day>07</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>07</day><month>6</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>35</volume><issue>22</issue><fpage>4846</fpage><lpage>4848</lpage><history><date date-type="received"><day>26</day><month>11</month><year>2018</year></date><date date-type="rev-recd"><day>21</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>4</day><month>6</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019. Published by Oxford University Press.</copyright-statement><copyright-year>2019</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="btz465.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Motivation</title><p>Genetic alterations lead to tumor progression and cell survival but also uncover cancer-specific vulnerabilities on gene dependencies that can be therapeutically exploited.</p></sec><sec id="s2"><title>Results</title><p>vulcanSpot is a novel computational approach implemented to expand the therapeutic options in cancer beyond known-driver genes unlocking alternative ways to target undruggable genes. The method integrates genome-wide information provided by massive screening experiments to detect genetic vulnerabilities associated to tumors. Then, vulcanSpot prioritizes drugs to target cancer-specific gene dependencies using a weighted scoring system based on well known drug-gene relationships and drug repositioning strategies.</p></sec><sec id="s3"><title>Availability and implementation</title><p>
<ext-link ext-link-type="uri" xlink:href="http://www.vulcanspot.org">http://www.vulcanspot.org</ext-link>.</p></sec><sec id="s4"><title>Supplementary information</title><p>
<xref ref-type="supplementary-material" rid="sup1">Supplementary data</xref> are available at <italic>Bioinformatics</italic> online.</p></sec></abstract><funding-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">National Institute of Health Carlos III</named-content></funding-source></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">ISCIII</named-content><named-content content-type="funder-identifier">10.13039/501100004587</named-content></funding-source></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Marie-Curie Career Integration</named-content></funding-source><award-id>CIG334361</award-id></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Paradifference Foundation</named-content></funding-source></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Severo Ochoa FPI</named-content></funding-source></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Spanish Ministry of Economy and Competitiveness</named-content></funding-source></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Comunidad de Madrid</named-content><named-content content-type="funder-identifier">10.13039/100012818</named-content></funding-source><award-id>S2017/ 65 BMD-3778</award-id></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">European Structural and Investment Fund</named-content></funding-source></award-group></funding-group><counts><page-count count="3"/></counts></article-meta></front><body><sec><title>1 Introduction</title><p>Tumor progression and cancer cell survival usually depends on acquired genetic alterations like Loss-of-Function (LoF) of tumor suppressor genes and Gain-of-Function (GoF) of oncogenes. Such genetic dependencies (GDs) may confer specific tumor vulnerabilities that have been proposed to be therapeutically exploited (i.e. synthetic lethality) enabling cancer cells to be targeted selectively (<xref rid="btz465-B3" ref-type="bibr">Brunen and Bernards, 2017</xref>). Massive gene LoF experiments by RNAi and CRISPR such as Cancer Dependency Map (DepMap, <xref rid="btz465-B12" ref-type="bibr">Tsherniak <italic>et al.</italic>, 2017</xref>) and drug screenings across cancer cell lines such as Cancer Cell Line Encyclopedia (CCLE) (<xref rid="btz465-B1" ref-type="bibr">Barretina <italic>et al.</italic>, 2012</xref>), Genomics of Drug Sensitivity in Cancer (GDSC, <xref rid="btz465-B7" ref-type="bibr">Iorio <italic>et al.</italic>, 2016</xref>) and Cancer Therapeutic Response Portal (CTRP, <xref rid="btz465-B10" ref-type="bibr">Seashore-Ludlow <italic>et al.</italic>, 2015</xref>) have been systematically performed seeking for GDs and novel biomarkers of drug response in cancer. These projects have encouraged the development of <italic>in silico</italic> drug prescription strategies to link genomic alterations or GDs to potential therapies (<xref rid="btz465-B2" ref-type="bibr">Bridgett <italic>et al.</italic>, 2017</xref>; <xref rid="btz465-B8" ref-type="bibr">Pi&#x000f1;eiro-Y&#x000e1;&#x000f1;ez <italic>et al.</italic>, 2018</xref>; <xref rid="btz465-B9" ref-type="bibr">Rubio-Perez <italic>et al.</italic>, 2015</xref>). Here we introduce vulcanSpot (VULnerable CANcer Spot), a novel webtool to expand and prioritize the cancer therapeutic options targeting tumor-specific GDs detected in user&#x02019;s query.</p></sec><sec><title>2 Methods and features</title><p>vulcanSpot includes three main steps: (i) genome-wide identification of GDs considering distinct cellular contexts in cancer, (ii) <italic>in silico</italic> prescription of drugs that directly target those GDs or mimic the GDs depletion employing transcriptional signatures and protein&#x02013;protein interaction (PPi) networks and (iii) therapeutic prioritization following the most relevant druggable associations (<xref ref-type="fig" rid="btz465-F1">Fig. 1</xref>).</p><sec><title>2.1 Identification of GDs in tumor-specific genotype contexts</title><p>vulcanSpot identifies GDs by integrating molecular profiles of DNA alterations and gene essentiality from the CCLE and DepMap datasets, respectively (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref>). To do this, genetic DNA alterations in protein-coding genes were classified into GoF and LoF based on their functional consequence (<xref rid="btz465-B5" ref-type="bibr">Futreal <italic>et al.</italic>, 2004</xref>). Then, cancer cell lines harboring a recurrent genetic alteration (Gene A) were interrogated using Kolmogorov-Smirnov test to evaluate whether there is a significant enrichment of such alteration across the ranked essentiality score (estimated by DepMap dependency score) for a given gene (Gene B) in all cell lines (<xref ref-type="fig" rid="btz465-F1">Fig.&#x000a0;1</xref>). This statistical analysis detects significant GDs for PanCancer scenario or lineage-specific context, being gene A an altered input gene and gene B essential for cell viability upon this genotype context (<xref ref-type="supplementary-material" rid="sup1">Supplementary Materials</xref> S3 and <xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. S1</xref>).
</p><fig id="btz465-F1" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>vulcanSpot workflow</p></caption><graphic xlink:href="btz465f1"/></fig></sec><sec><title>2.2 Drug prescription on vulnerable GDs</title><p>vulcanSpot distinguishes three types of vulnerable GDs (<xref ref-type="fig" rid="btz465-F1">Fig.&#x000a0;1</xref>) depending on gene A and/or gene B druggability with current drugs (FDA approved and clinical trials).</p><p>
<italic>In silico</italic> drug prescription is performed following two complementary approaches. First, vulcanSpot assesses the druggability of GDs using PanDrugs, a methodology to prioritize candidate drugs evaluating gene therapeutic actionability (<xref rid="btz465-B8" ref-type="bibr">Pi&#x000f1;eiro-Y&#x000e1;&#x000f1;ez <italic>et al.</italic>, 2018</xref>). Thus, vulcanSpot integrates: (i) PanDrugs database information about genes that can be directly targeted by a drug (direct targets) and (ii) PanDrugs drug score (DScore) to evaluate drug response and treatment suitability of each identified GD. Second, vulcanSpot extends the repertoire of suggested therapies targeting GDs using a drug repositioning approach. This method prioritizes those drugs whose transcriptional activity mimic the transcriptional change of a knocked-down gene of interest. To do so, we calculate the consensus gene expression signatures from a catalog of gene knock-down (KD) and compound perturbations (CP) expression profiles in cancer cell lines from the LINCS L1000 dataset (<xref rid="btz465-B11" ref-type="bibr">Subramanian <italic>et al.</italic>, 2017</xref>). A KDCP score representing the similarity between every pair of KD&#x02013;CP signatures is calculated using the Total Enrichment Score (<xref rid="btz465-B6" ref-type="bibr">Iorio <italic>et al.</italic>, 2010</xref>). KDCP score also integrates PPi networks information (<xref rid="btz465-B4" ref-type="bibr">Cowley <italic>et al.</italic>, 2012</xref>). Distance between network nodes is employed to prioritize those drug compounds that act closer to the target of interest (see <xref ref-type="supplementary-material" rid="sup1">Supplementary Material</xref> S4.2).</p></sec><sec><title>2.3 Therapeutic prioritization</title><p>vulcanSpot final output offers a ranking of prioritized drugs to target statistically significant GDs (FDR &#x0003c; 0.25). The ranking is ordered taking into account DScore, KDCP score and the experimental validation of the proposed GD&#x02013;drug pairs using drug sensitivity data from GDSC and CTRP (see <xref ref-type="supplementary-material" rid="sup1">Supplementary Materials S5&#x02013;S8</xref>).</p></sec><sec><title>2.4 Implementation details</title><p>vulcanSpot back-end was written in JavaScript using the Node.js runtime environment, and it is supported by a PostgreSQL database to store the data in a relational model. The front-end is written in JavaScript using the React library for functional components, and the Material-UI library for the presentation layer. vulcanSpot also offers programmatic access through a RESTful API.</p></sec></sec><sec><title>3 Conclusions</title><p>We have developed vulcanSpot, a novel genome-wide method to exploit massive screenings data to identify GDs and prescribe drugs using a combination of known drug-gene relationships and drug repositioning strategies. This methodology uncovers novel therapeutic strategies to target cancer-specific vulnerabilities. vulcanSpot and its full documentation are accessible at <ext-link ext-link-type="uri" xlink:href="http://www.vulcanspot.org/">http://www.vulcanspot.org/</ext-link>.</p></sec><sec><title>Funding</title><p>This work was supported by National Institute of Health Carlos III (ISCIII); Marie-Curie Career Integration Grant (CIG334361); and Paradifference Foundation. J.P.-P. is supported by Severo Ochoa FPI grant doctoral fellowship by the Spanish Ministry of Economy and Competitiveness. C.F.-T. is supported by Comunidad de Madrid [S2017/ 65 BMD-3778] (LINFOMAS-CM) co-financed by European Structural and Investment Fund.</p><p>
<italic>Conflict of Interest</italic>: none declared.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1"><label>btz465_Supplementary_Data</label><media xlink:href="btz465_supplementary_data.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list id="ref1"><title>References</title><ref id="btz465-B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Barretina</surname><given-names>J.</given-names></name></person-group>
<etal>et al</etal> (<year>2012</year>) 
<article-title>The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>. <source>Nature</source>, <volume>483</volume>, <fpage>603</fpage>&#x02013;<lpage>607</lpage>.<pub-id pub-id-type="pmid">22460905</pub-id></mixed-citation></ref><ref id="btz465-B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bridgett</surname><given-names>S.</given-names></name></person-group>
<etal>et al</etal> (<year>2017</year>) 
<article-title>CancerGD: a resource for identifying and interpreting genetic dependencies in cancer</article-title>. <source>Cell Syst</source>., <volume>5</volume>, <fpage>82</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">28711281</pub-id></mixed-citation></ref><ref id="btz465-B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brunen</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Bernard</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>) 
<article-title>Exploiting synthetic lethality to improve cancer therapy</article-title>. <source>Nat. Rev. Clin. Oncol</source>., <volume>14</volume>, <fpage>331</fpage>&#x02013;<lpage>332</lpage>.<pub-id pub-id-type="pmid">28352131</pub-id></mixed-citation></ref><ref id="btz465-B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cowley</surname><given-names>M.J.</given-names></name></person-group>
<etal>et al</etal> (<year>2012</year>) 
<article-title>PINA v2.0: mining interactome modules</article-title>. <source>Nucleic Acids Res</source>., <volume>40</volume>, <fpage>D862</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">22067443</pub-id></mixed-citation></ref><ref id="btz465-B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Futreal</surname><given-names>P.A.</given-names></name></person-group>
<etal>et al</etal> (<year>2004</year>) 
<article-title>A census of human cancer genes</article-title>. <source>Nat. Rev. Cancer</source>, <volume>4</volume>, <fpage>177</fpage>&#x02013;<lpage>183</lpage>.<pub-id pub-id-type="pmid">14993899</pub-id></mixed-citation></ref><ref id="btz465-B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Iorio</surname><given-names>F.</given-names></name></person-group>
<etal>et al</etal> (<year>2010</year>) 
<article-title>Discovery of drug mode of action and drug repositioning from transcriptional responses</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>107</volume>, <fpage>14621</fpage>&#x02013;<lpage>14626</lpage>.<pub-id pub-id-type="pmid">20679242</pub-id></mixed-citation></ref><ref id="btz465-B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Iorio</surname><given-names>F.</given-names></name></person-group>
<etal>et al</etal> (<year>2016</year>) 
<article-title>A landscape of pharmacogenomic interactions in cancer</article-title>. <source>Cell</source>, <volume>166</volume>, <fpage>740</fpage>&#x02013;<lpage>754</lpage>.<pub-id pub-id-type="pmid">27397505</pub-id></mixed-citation></ref><ref id="btz465-B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pi&#x000f1;eiro-Y&#x000e1;&#x000f1;ez</surname><given-names>E.</given-names></name></person-group>
<etal>et al</etal> (<year>2018</year>) 
<article-title>PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data</article-title>. <source>Genome Med</source>., <volume>10</volume>, <fpage>41.</fpage><pub-id pub-id-type="pmid">29848362</pub-id></mixed-citation></ref><ref id="btz465-B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rubio-Perez</surname><given-names>C.</given-names></name></person-group>
<etal>et al</etal> (<year>2015</year>) 
<article-title>In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities</article-title>. <source>Cancer Cell</source>, <volume>27</volume>, <fpage>382</fpage>&#x02013;<lpage>396</lpage>.<pub-id pub-id-type="pmid">25759023</pub-id></mixed-citation></ref><ref id="btz465-B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Seashore-Ludlow</surname><given-names>B.</given-names></name></person-group>
<etal>et al</etal> (<year>2015</year>) 
<article-title>Harnessing connectivity in a large-scale small-molecule sensitivity dataset</article-title>. <source>Cancer Discov</source>., <volume>5</volume>, <fpage>1210</fpage>&#x02013;<lpage>1223</lpage>.<pub-id pub-id-type="pmid">26482930</pub-id></mixed-citation></ref><ref id="btz465-B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Subramanian</surname><given-names>A.</given-names></name></person-group>
<etal>et al</etal> (<year>2017</year>) 
<article-title>A next generation connectivity map: L1000 platform and the first 1, 000, 000 profiles</article-title>. <source>Cell</source>, <volume>171</volume>, <fpage>1437</fpage>&#x02013;<lpage>1452</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation></ref><ref id="btz465-B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tsherniak</surname><given-names>A.</given-names></name></person-group>
<etal>et al</etal> (<year>2017</year>) 
<article-title>Defining a cancer dependency map</article-title>. <source>Cell</source>, <volume>170</volume>, <fpage>564</fpage>&#x02013;<lpage>576.e16</lpage>.<pub-id pub-id-type="pmid">28753430</pub-id></mixed-citation></ref></ref-list></back></article>